A new analysis of cancer drug development by researchers at the Institute of Cancer Research, London, shows that the more revolutionary a new cancer drug is, the longer it takes to reach patients in the UK’s National Health Service healthcare system. In other words, refinements on earlier drugs or drugs which are more conventional in their effects make it to the marketplace faster
More...